Premium
This is an archive article published on May 10, 2011

Dr Reddy’s launches Peg-grafeel injection in India

Dr Reddy’s Laboratories said it has launched a generic version of pegfilgrastim injection,used in cancer therapy under the brand ‘Peg- grafeel’ in India.

Listen to this article
Dr Reddy’s launches Peg-grafeel injection in India
x
00:00
1x 1.5x 1.8x

Dr Reddy’s Laboratories today said it has launched a generic version of pegfilgrastim injection,used in cancer therapy under the brand ‘Peg- grafeel’ in India.

“Peg-grafeel will offer patients in India an important alternative. An affordable pegfilgrastim will define the way patients undergoing treatment with chemotherapy can reduce the duration of neutropenia…,” Dr Reddy’s Vice-Chairman and CEO GV Prasad said in a filing to the Bombay Stock Exchange (BSE).

Neutropenia is a condition in which a patient has lower than normal white blood cell count,a common side effect of chemotherapy.

Story continues below this ad

Pegfilgrastim developed by Amgen Inc was approved for use in 2002,and is sold as Neulasta in the US market and European Union,it added.

Dr Reddy’s said its Peg-grafeel is priced at Rs 8,865 per vial. According to the company,the product is priced at nearly 25 per cent of the originator brand in India.

“We also intend to market Peg-grafeel globally,on our own and through our partners,” Prasad said.

Pegfilgrastim is marketed in India by several companies,including F Hoffmann-La Roche.

Story continues below this ad

Shares of Dr Reddy’s Laboratories today closed at Rs 1,591 on the BSE,down 0.19 per cent from the previous close.


📣 For more lifestyle news, click here to join our WhatsApp Channel and also follow us on Instagram

Latest Comment
Post Comment
Read Comments
Advertisement
Advertisement
Advertisement
Advertisement